Michael Wang, MD, and Nakhle Saba, MD, highlight current frontline treatment approaches for mantle cell lymphoma.
Back
Navigating BTK Inhibition and Second-Line Treatment in Mantle Cell Lymphoma: Updates From ASH 2025
Michael Wang, MD, and Nakhle Saba, MD, provide a comprehensive overview of the evolving treatment landscape for mantle cell lymphoma, highlighting how frontline strategies and later-line targeted therapies are reshaping clinical practice. They review emerging data on BTK and BCL2 inhibition, novel agents such as sonrotoclax, and combination approaches presented at the 2025 ASH Annual Meeting and Exposition. Wang and Saba also explore ongoing research priorities that may further refine treatment sequencing and improve long-term outcomes for patients with mantle cell lymphoma.
Navigating BTK Inhibition and Second-Line Treatment in Mantle Cell Lymphoma: Updates From ASH 2025
Episodes
All
All
Michael Wang, MD, and Nakhle Saba, MD, discuss factors that drive BTK inhibitor selection in second-line mantle cell lymphoma.
Michael Wang, MD, and Nakhle Saba, MD, detail phase 1/2 findings for sonrotoclax in relapsed/refractory mantle cell lymphoma.
Michael Wang, MD, and Nakhle Saba, MD, discuss data for the frontline combination of zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma.
Michael Wang, MD, and Nakhle Saba, MD, discuss the management of adverse effects associated with BTK inhibition in mantle cell lymphoma.
Michael Wang, MD, and Nakhle Saba, MD, discuss how ongoing research is shaping the evolving role of BTK and BCL2 inhibitors in mantle cell lymphoma.
Michael Wang, MD, and Nakhle Saba, MD, highlight other key mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition.
Michael Wang, MD, and Nakhle Saba, MD, discuss ongoing research to watch in mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5